The wild type C57BL/6 mice were immunized three times with VACCINE (1 μg) combined with different dose formulation of GM-CSF and IFN-α in a 2-week interval. (A) 7 days after the third immunization, DTH were tested at 24 hours after HBsAg challenge at footpads of immunized mice. (B) 7 days after the third immunization, serum of immunized mice were collected for anti-HBsAg test by ELISA. Bars represent mean ± SEM from 3 independent experiments, * P < 0.05; ** P < 0.01; ns, not significant.
Supplementary Figure 3: GM-CSF/IFN-α/VACCINE elicit cellular immunity against AAV/HBV infection. (A) 14 days
after the fourth immunization, the spleen cells were stimulated with 10 μg/mL HBsAg for 18 hours in vitro. Cells were incubated for 6 hours with PMA/Ionomycin (100 ng/mL / 1μg/mL) as a positive control. 
Ly6G
-monocytes were sorted from PBMC of male wild-type C57BL/6 (n = 50). (B) Conventional CD8 + T cells were sorted from spleen cells of AAV8-1.3HBV mice and co-cultured with HBsAg (10 μg/mL)-pulsed MoDC which generated from GM-CSF or GM-CSF/IFN-α at ratio 10:1 for 72 hours. CD3/CD28 (1μg/mL / 100 ng/mL) was used as a positive control. + granulocytes. Data are pooled from two independent experiments with 5 mice per group. Bars are shown as mean ± SEM. ns, not significant.
